Key Highlights

  • Total Revenue was USD 24,586 thousand versus 30,340 thousand, and product sales were USD 24,546 thousand versus 30,340 thousand.
  • Cost of sales was USD 6,487 thousand versus 6,113 thousand; total costs were USD 43,104 thousand versus 42,518 thousand.
  • Operating loss was USD 18,518 thousand versus 12,178 thousand; net loss was USD 16,224 thousand versus 9,816 thousand.
  • Net loss per share was USD 0.39 versus USD 0.24, and cash and cash equivalents were USD 66,717 thousand.

Revenue

RxSight, Inc. (NASDAQ:RXST), a company that markets the RxSight Light Adjustable Lens system for cataract surgery, filed its Quarterly Report for the period ended September 30, 2026. Total revenue was USD 24,586 thousand, compared with USD 30,340 thousand in the third quarter of 2025.

Product sales were USD 24,546 thousand versus USD 30,340 thousand, and license and collaboration revenue was USD 40 thousand with none in the prior-year quarter. For the nine months ended September 30, 2026, total revenue was USD 89,220 thousand versus USD 101,871 thousand, including product sales of USD 82,680 thousand and license and collaboration revenue of USD 6,540 thousand.

Analyst estimates were EPS of negative USD 0.31 against reported EPS of negative USD 0.39, and revenue of USD 27.2 million against reported revenue of USD 24.6 million.

Costs and Loss from Operations

Cost of sales was USD 6,487 thousand versus USD 6,113 thousand. Selling, general and administrative expense was USD 27,404 thousand versus USD 27,345 thousand, and Research and Development expense was USD 9,213 thousand versus USD 9,060 thousand.

Total costs and expenses were USD 43,104 thousand versus USD 42,518 thousand, and the loss from operations was USD 18,518 thousand versus USD 12,178 thousand. For the nine months, total costs and expenses were USD 139,338 thousand versus USD 138,725 thousand, and the loss from operations was USD 50,118 thousand versus USD 36,854 thousand.

Net Loss and Earnings per Share

Interest and other income was USD 2,325 thousand versus USD 2,376 thousand, and interest expense was USD 3 thousand versus USD 4 thousand. The loss before income taxes was USD 16,196 thousand versus USD 9,806 thousand, and income tax expense was USD 28 thousand versus USD 10 thousand.

The net loss was USD 16,224 thousand versus USD 9,816 thousand, and comprehensive loss was USD 16,265 thousand versus USD 9,639 thousand. Basic and diluted net loss per share were USD 0.39 versus USD 0.24, on 41,705,436 weighted average shares versus 40,965,219. For the nine months, net loss per share was USD 1.07 versus USD 0.73, on 41,502,275 weighted average shares versus 40,741,219. Selling, general and administrative expense for the nine months was USD 89,678 thousand versus USD 84,956 thousand, and research and development expense was USD 27,922 thousand versus USD 29,644 thousand.

Items to Follow

Investors can follow cash, investments and the collaboration with Alcon. Cash and cash equivalents were USD 66,717 thousand at September 30, 2026, versus USD 19,949 thousand at December 31, 2025, and short-term investments were USD 187,966 thousand versus USD 208,179 thousand.

Inventories were USD 39,593 thousand versus USD 31,559 thousand. The filing reports net cash provided by Operating Activities of USD 24.8 million for the nine months versus net cash used of USD 14.4 million in the prior-year period, and refers to an upfront payment under the RxSight-Alcon Collaboration Agreement.